Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
GTx, Inc. (NASDAQ: GTXI) shares plunged 65.54 percent to close at $1.43 a share Monday. The stock traded between $1.31 and $1.69 on volume of 17.13 million shares traded. The company announced that two Phase 3 enobosarm clinical trials failed to “meet the overall criteria for the co-primary responder endpoints of lean body mass and physical function as agreed upon” with the FDA.
Get more information on GTx and free access to the in-depth equity report at:
NTELOS Holdings Corp. (NASDAQ: NTLS) shares fell 16.24 percent to close at $15.27 a share Monday. The stock traded between $15.15 and $16.90 on volume of 946,694 shares traded. The company was added to FBR Capital’s Top Picks list as a short. The firm currently has an “underperform” rating and a price target of $5.00 on the stocks. Shares of NTELOS have gained approximately 16.0 percent year-to-date.
Get more information on NTELOS and free access to the in-depth equity report at:
Pinnacle Entertainment, Inc. (NYSE: PNK) shares increased 3.90 percent to close at $22.65 a share Monday. The stock traded between $22.01 and $22.65 on volume of 951,499 shares traded. The company announced that it has agreed to sell Lumiere Place Casino and hotels to Tropicana Entertainment Inc. for approximately $260.0 million. Shares of Pinnacle Entertainment have gained approximately 43.0 percent year-to-date.
Get more information on Pinnacle Entertainment and free access to the in-depth equity report at:
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) shares spiked 3.92 percent to close at $6.90 a share Monday. The stock traded between $6.79 and $8.40 on volume of 11.20 million shares traded. The company announced that its epilepsy treatment, Trokendi XR, has received final approval from the FDA.
Get more information on Supernus Pharmaceuticals and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...